Vascular Medicine

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to browse AJSM online!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schrör, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schrör, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Vascular Medicine, Vol. 3, No. 3, 247-251 (1998)
DOI: 10.1177/1358836X9800300312

Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel

Karsten Schrör

Institut für Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany

Antiplatelet compounds interfere with the platelet activation cascade at different levels. The antiplatelet effect of the thienopyridine, clopidogrel, results from antagonism of a platelet ADP receptor, P2T, resulting in inhibition of platelet activation. This antagonism is non-competitive, irreversible, and results in a 50-70% inhibition of platelet fibrinogen binding. Additionally, clopidogrel may also antagonize the ADP-induced inhibition of adenylate cyclase, possibly resulting in an elevated platelet cyclic adenosine monophosphate level after stimulation by an appropriate agonist, such as prostacyclin. This spectrum of antiplatelet activities is different from that of aspirin. Further, clopidogrel is associated with a reduction in gastrointestinal hemorrhage, making it a valuable therapeutic alternative to aspirin in oral, long-term prevention of atherothrombotic vascular occlusion.

Key Words: ADP • atherosclerosis • clopidogrel • platelet • thrombosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
A Blann
Antiplatelet therapy and the vascular tree
Heart, January 1, 2006; 92(1): 3 - 4.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. L. Orford, R. Lennon, S. Melby, P. Fasseas, M. R. Bell, C. S. Rihal, D. R. Holmes, and P. B. Berger
Frequency and correlates of coronary stent thrombosis in the modern era: Analysis of a single center registry
J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1567 - 1572.
[Abstract] [Full Text] [PDF]